RxDoctor Payments Data

David Butuk, MD

Family Medicine · Meridian, IDNPI 1942250972

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $203,797 of the $206,193 with a category attached, or 98.8%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 84.8% of it on its own, with 13 other manufacturers making up the rest. Among family medicine clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$206,193in general payments, 2019–2025

Across 124 payments — averaging $1662.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$175K
  • Shire North American Group Inc$29K
  • Boehringer Ingelheim International GmbH$2K
  • Novo Nordisk$80
  • AbbVie$78
  • Astellas Pharma US Inc$69
  • plus $184 from 8 others
$15,059,660in research payments, 2019–2025

Across 2,948 payments — averaging $5108.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$7.4M
  • Eli Lilly$3.7M
  • Merck$1.2M
  • Novo Nordisk AS$793K
  • Boehringer Ingelheim$673K
  • Novartis$386K
  • plus $983K from 8 others

What the payments were for

  • Consulting fees$203,79799%
  • Travel & lodging$1,3751%
  • Food & beverage$1,0010%
  • Gifts$200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$206,193 in reported general payments places this provider in the 95th percentile of 803 family medicine providers in Idaho.

See all family medicine providers in Idaho

Medicare billing

Part B allowed, 2024
$6,082
Medicare patients
28
Services billed
177

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide26$24,996
OzempicSemaglutide23$23,884
FarxigaDapagliflozin Propanediol18$14,014
EliquisApixaban17$9,679
Levothyroxine Sodium62$877
Atorvastatin Calcium77$726
Omeprazole35$565
Risedronate Sodium16$538
Metformin Hcl ErMetformin Hcl61$479
Lisinopril60$458
Amlodipine Besylate51$401
Gabapentin22$401
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide21$352
Losartan Potassium27$317
Metoprolol Succinate12$315

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$13$24,99626 claims
Novo NordiskOzempic$80$23,88423 claims
PfizerEliquis$45$9,67917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 803 family medicine providers in Idaho.

Other family medicine in Meridian

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →